Abstract:Background and objective: Overexpression of ATP-binding cassette (ABC) transporters, which play a key role in the development of multidrug resistance (MDR), is a significant impediment to successful cancer treatment. Sunitinib is an ATP-competitive multi-targeted tyrosine kinase inhibitor. In this study, we investigated in vitro the possible interaction of sunitinib with the major members of the ABC transporters: P-glycoprotein (P-gp, ABCB1), multidrug resistance protein 1 (MRP1, ABCC1), breast cancer resistance protein (BCRP, ABCG2) and lung-resistance protein (LRP). Methods: Cytotoxicity tests were performed using the MTT assay; The intracellular accumulation of doxorubicin and rhodamine 123 (Rho123) was analysed by flow cytometry; Membrane vesicles were prepared by the nitrogen cavitation and transport assays were performed using the rapid filtration method to confirm the effect of sunitinib on the transporter activity of ABCG2; Western Blotting was used to determine the protein expression; and reverse transcription-PCR was used to assess the expression of ABCG2 at mRNA level. Results: The IC 50 concentration for parental cell line S1 to topotecan or doxorubicin were 0.135 ± 0.056 µM and 0.165 ± 0.009 µM, respectively; However, the concentration of topotecan or doxorubicin required to inhibit ABCG2- overexpressing cell line S1-M1-80 by 50% was about 5.132 ± 2.024 and 6.845 ± 1.035 µM; Coincubation with 2.5 sunitinib, the concentrations required to inhibit the growth of S1-M1-80 cells by 50% for topotecan was 0.091 ± 0.012 µM, and for doxorubicin was 0.181 ± 0.037 µM, respectively. Sunitinib potently reverses ABCG2-mediated resistance to topotecan and doxorubicin in vitro and has no significant reversal effect on ABCB1-, ABCC1- and LRP-mediated drug resistance, although a small synergetic effect was observed in combining sunitinib and conventional chemotherapeutic agents in ABCB1-overexpressing MCF-7/adr and parental sensitive MCF-7 cells, ABCC1-overexpressing C-A120 and parental sensitive KB-3-1 cells. Sunitinib significantly increased intracellular accumulation of rhodamine 123 and doxorubicin and remarkably inhibited the efflux of rhodamine-123 in ABCG2-overexpressing cells, and also profoundly inhibited the transport of [ 3 H]-methotrexate by ABCG2. However, sunitinib did not affect the expression of ABCG2 at mRNA or protein levels. In addition, sunitinib did not block the phosphorylation of Akt and Erk1/2 in ABCG2-overexpressing or parental sensitive cells. Conclusions: Sunitinib reverses ABCG2-mediated MDR through inhibiting the drug efflux function of ABCG2. These findings may be useful for cancer combinational therapy with sunitinib in the clinic. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1533.

Drug interaction between sunitinib and cimetidine and contribution of the efflux transporter ATP-binding cassette C2 to biliary excretion of sunitinib in rats

Effects of CYP3A inhibitors ketoconazole, voriconazole, and itraconazole on the pharmacokinetics of sunitinib and its main metabolite in rats

The CYP3A inducer dexamethasone affects the pharmacokinetics of sunitinib by accelerating its metabolism in rats

Effect of Cimetidine on Metformin Pharmacokinetics and Endogenous Metabolite Levels in Rats

Effect of isavuconazole on the pharmacokinetics of sunitinib and its mechanism

Renal tubular transporter-mediated interactions between mirogabalin and cimetidine in rats

Sensitization of ABCG2-overexpressing Cells to Conventional Chemotherapeutic Agent by Sunitinib Was Associated with Inhibiting the Function of ABCG2.

Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model

Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability

The Pharmacokinetic Interaction Between Irinotecan and Sunitinib

The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer: preliminary evidence of a potentially common drug interaction

Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists

Abstract 1533: Sunitinib reverses ABCG2/BCRP-mediated multidrug resistance by inhibiting its efflux activity

Quantitative contributions of hepatic and renal organic cation transporters to the clinical pharmacokinetic cimetidine-metformin interaction

Sunitinib Impairs the Proliferation and Function of Human Peripheral T Cell and Prevents T-cell-mediated Immune Response in Mice.

Impaired Clearance of Sunitinib Leads to Metabolic Disorders and Hepatotoxicity

In vivo cimetidine inhibits hepatic CYP2C6 and CYP2C11 but not CYP1A1 in adult male rats

The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6

Pharmacokinetic interaction between sunitinib and ramipril in rats

In Vitro Assessment of the Role of Endoplasmic Reticulum Stress in Sunitinib-Induced Liver and Kidney Toxicity

Inhibitory Effect Of Silybin On Pharmacokinetics Of Imatinib In Vivo And In Vitro